CompanyDrug

Suzhou GenAssist’s GEN6050 Receives US FDA Pre-IND Acceptance for Duchenne Muscular Dystrophy Treatment

CompanyDeals

Sinopharm Partners with Fudan University to Establish National Innovation Platform

CompanyDrug

Reistone Biopharma’s Edralbrutinib Earns Orphan Drug Designation for NMOSD from US FDA

CompanyDeals

Lingyi Biotechnology Secures RMB 100 Million in Series A Funding for Gene Therapy Pipeline

CompanyDrug

Henlius Biotech’s HLX26 and HaiSiZhuang Combo for NSCLC Gets NMPA Phase II Approval

CompanyDeals

Shanghai Junshi Biosciences Inks Exclusive License Deal with Dr. Reddy’s Laboratories for Tuoyi

CompanyDeals

Sinopharm Partners with Shenzhen to Boost High-End Medical Device and Pharmaceutical Innovation

CompanyDeals

XtalPi Inc. and China Pharmaceutical University Launch Joint AI Research Center in China

CompanyMedical Device

Omega Medical Imaging’s Soteria.AI Receives FDA Approval for Interventional Cardiology

Policy / Regulatory

NMPA Extends Public Feedback Period for ‘Drug Standardization Management Measures’ in China

CompanyDeals

Hasten Biopharm Acquires Commercial Rights to Rocephin in China from Roche

Company

Mindray Reports Strong YOY Growth in 2022 and Q1 2023 Financial Results